CCR5 ‐Mediated Reprogramming of Regulatory T Cells and Monocytic‐Myeloid‐Derived Suppressor Cells in Young Dyslipidemic Individuals: A Plausible Therapeutic Approach
Immunology · 2025
DOI: 10.1111/imm.13941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2025. Verfasst von Komal Sagar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, All India Institute of Medical Sciences, AIIMS, New Delhi, India. Hauptthemen laut MEDLINE: Receptors, CCR5, T-Lymphocytes, Regulatory, Monocytes, Dyslipidemias. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: University Grants Commission, India, Indian Council of Medical Research, University Grants Commission.
Abstract (Originalsprache)
Chemokine receptor CCR5 is upregulated in the regulatory T cells (Tregs) and monocytic‐myeloid‐derived suppressor cells (M‐MDSCs) of young dyslipidemic individuals. In this study, we investigated the role of CCR5 in regulating the phenotypic and functional plasticity of Tregs and M‐MDSCs during the preclinical phase of atherosclerosis. Inflammatory conditions induce a phenotypic shift in Tregs and M‐MDSCs, characterised by enhanced expression of CCR5 and pro‐inflammatory cytokines. Tregs from dyslipidemic (DLP) and coronary artery disease (CAD) patients exhibited a mixed Th1/Th17/Treg phenotype, whilst M‐MDSCs displayed elevated markers of activation and inflammation. CCR5 inhibition via DAPTA (10 −8 M) restored the immune suppressive phenotype and function of Tregs and M‐MDSCs in vitro. Migration of dysfunctional Tregs and M‐MDSCs to CCL5 stimulus was also reduced after DAPTA treatment in vitro. In vivo, DAPTA reduced IL‐12 expression and elevated IL‐10 expression in Tregs and M‐MDSCs. Therapeutically targeting CCR5 in Tregs and M‐MDSCs of young naive dyslipidemic individuals aids in the dampening of early inflammation and can prevent the progression of atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, All India Institute of Medical Sciences, AIIMS, New Delhi, India.
- Department of Biophysics, AIIMS, New Delhi, India.
- Department of Cardiology, AIIMS, New Delhi, India.
- Department of Cardiothoracic and Vascular Surgery, AIIMS, New Delhi, India.
- Department of Pathology, AIIMS, New Delhi, India.
Förderung
- University Grants Commission, India
- Indian Council of Medical Research
- University Grants Commission
Zitieren
APA
Sagar, K., Akhtar, S., Kumar, N., Tomar, A. K., Roy, A., Hote, M. P., Arava, S., Yadav, S., & Sharma, A. (2025). CCR5 ‐Mediated Reprogramming of Regulatory T Cells and Monocytic‐Myeloid‐Derived Suppressor Cells in Young Dyslipidemic Individuals: A Plausible Therapeutic Approach. Immunology. https://doi.org/10.1111/imm.13941
Vancouver
Sagar K, Akhtar S, Kumar N, Tomar AK, Roy A, Hote MP, et al. CCR5 ‐Mediated Reprogramming of Regulatory T Cells and Monocytic‐Myeloid‐Derived Suppressor Cells in Young Dyslipidemic Individuals: A Plausible Therapeutic Approach. Immunology. 2025. doi:10.1111/imm.13941
BibTeX
@article{Sagar2025,
author = {Sagar, Komal and Akhtar, Shamima and Kumar, Nikita and Tomar, Anil Kumar and Roy, Ambuj and Hote, Milind P and Arava, Sudheer and Yadav, Savita and Sharma, Alpana},
title = {CCR5 ‐Mediated Reprogramming of Regulatory T Cells and Monocytic‐Myeloid‐Derived Suppressor Cells in Young Dyslipidemic Individuals: A Plausible Therapeutic Approach},
journal = {Immunology},
year = {2025},
doi = {10.1111/imm.13941}
}
EUVIMED